Vaxcyte, Inc. announced that it has progressed to Stage 2 of its Phase 2 infant study for the VAX-31 pneumococcal conjugate vaccine after a review of Stage 1 safety and tolerability data. VAX-31 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback